NASDAQ:ACRX AcelRx Pharmaceuticals (ACRX) Stock Price, News & Analysis → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Free ACRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.49▼$0.8652-Week Range N/AVolume243,500 shsAverage Volume137,683 shsMarket Capitalization$14.58 millionP/E RatioN/ADividend YieldN/APrice Target$4.63 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability Get AcelRx Pharmaceuticals alerts: Email Address AcelRx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside∞ Upside$4.63 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.41Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.40) to ($0.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.42 out of 5 starsMedical Sector742nd out of 929 stocksPharmaceutical Preparations Industry347th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingAcelRx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAcelRx Pharmaceuticals has received no research coverage in the past 90 days.Read more about AcelRx Pharmaceuticals' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ACRX. Previous Next 0.0 Dividend Strength Dividend YieldAcelRx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcelRx Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAcelRx Pharmaceuticals has received a 53.29% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Sufentanil" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for AcelRx Pharmaceuticals is -2.41. Previous Next N/A News and Social Media Coverage Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AcelRx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of AcelRx Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 19.79% of the stock of AcelRx Pharmaceuticals is held by institutions.Read more about AcelRx Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for AcelRx Pharmaceuticals are expected to decrease in the coming year, from ($0.40) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AcelRx Pharmaceuticals is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AcelRx Pharmaceuticals is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monetary GoldTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. About AcelRx Pharmaceuticals Stock (NASDAQ:ACRX)AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.Read More Ad Monetary GoldTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. ACRX Stock News HeadlinesJanuary 11, 2024 | markets.businessinsider.comTalphera’s Strategic Rebrand and Niyad’s Market Potential Bolster Buy RatingJanuary 9, 2024 | msn.comAcelRx announces rebranding with name change to TalpheraJanuary 9, 2024 | finance.yahoo.comAcelRx Announces Rebranding With Name Change to Talphera, Inc.December 22, 2023 | benzinga.comAcelRx Pharmaceuticals Stock (NASDAQ:ACRX) Dividends: History, Yield and DatesDecember 12, 2023 | finance.yahoo.comAcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United StatesNovember 22, 2023 | msn.comAcelRx Pharmaceuticals files for $150M mixed shelfNovember 9, 2023 | finanznachrichten.deAcelRx Pharmaceuticals, Inc.: AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 7, 2023 | msn.comAcelRx Pharmaceuticals Q3 2023 Earnings PreviewNovember 7, 2023 | finance.yahoo.comAcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical StudyOctober 26, 2023 | finance.yahoo.comAcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023October 3, 2023 | finance.yahoo.comAcelRx Receives IDE Approval for Niyad and Advances to a Single Registration StudySeptember 12, 2023 | msn.comAcelRx CEO buys 10,000 sharesSeptember 12, 2023 | finance.yahoo.comInsider Buying: CEO Vincent Angotti Acquires 10,000 Shares of AcelRx Pharmaceuticals IncAugust 22, 2023 | finance.yahoo.comWhat Makes AcelRx Pharmaceuticals (ACRX) a New Buy StockAugust 18, 2023 | markets.businessinsider.comPositive Report for Acelrx (ACRX) from H.C. WainwrightAugust 13, 2023 | finance.yahoo.comAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q2 2023 Earnings Call TranscriptAugust 12, 2023 | finanznachrichten.deAcelRx Pharmaceuticals, Inc.: AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 11, 2023 | finance.yahoo.comQ2 2023 AcelRx Pharmaceuticals Inc Earnings CallAugust 11, 2023 | finance.yahoo.comAcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 11, 2023 | finance.yahoo.comAcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue EstimatesJuly 28, 2023 | finance.yahoo.comAcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023July 21, 2023 | finance.yahoo.comAcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq RulesJuly 18, 2023 | seekingalpha.comAcelRx Pharmaceuticals launches ~$10M private placement of sharesJuly 18, 2023 | finance.yahoo.comAcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesJune 17, 2023 | finance.yahoo.comACRX - AcelRx Pharmaceuticals, Inc.See More Headlines Receive ACRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today5/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACRX CUSIPN/A CIK1427925 Webwww.acelrx.com Phone(650) 216-3500Fax650-216-6500Employees19Year FoundedN/APrice Target and Rating Average Stock Price Target$4.63 High Stock Price Target$5.00 Low Stock Price Target$4.25 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$47.76 million Net MarginsN/A Pretax Margin-3,711.25% Return on Equity-81.54% Return on Assets-46.02% Debt Debt-to-Equity RatioN/A Current Ratio4.04 Quick Ratio4.04 Sales & Book Value Annual Sales$1.77 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.65 per share Price / BookN/AMiscellaneous Outstanding Shares16,950,000Free Float16,443,000Market Cap$14.58 million OptionableOptionable Beta0.52 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Vincent J. Angotti (Age 56)CEO & Director Comp: $906.54kDr. Pamela Pierce Palmer M.D. (Age 61)Ph.D., Co-Founder, Chief Medical Officer & Director Comp: $699.75kMr. Raffi Mark Asadorian (Age 55)Chief Financial Officer Comp: $637.5kMr. Anil N. Dasu (Age 61)Chief Engineering Officer Comp: $478.09kKey CompetitorsEdesa BiotechNASDAQ:EDSAFSD PharmaNASDAQ:HUGETonix PharmaceuticalsNASDAQ:TNXPPieris PharmaceuticalsNASDAQ:PIRSNeuroSense TherapeuticsNASDAQ:NRSNView All CompetitorsInsidersVincent J AngottiBought 10,000 shares on 12/13/2023Total: $7,300.00 ($0.73/share)Vincent J AngottiBought 10,000 shares on 9/11/2023Total: $8,000.00 ($0.80/share)Pamela P PalmerSold 9,514 sharesTotal: $11,131.38 ($1.17/share)View All Insider Transactions ACRX Stock Analysis - Frequently Asked Questions Should I buy or sell AcelRx Pharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACRX shares. View ACRX analyst ratings or view top-rated stocks. What is AcelRx Pharmaceuticals' stock price target for 2024? 2 analysts have issued 1-year price targets for AcelRx Pharmaceuticals' stock. Their ACRX share price targets range from $4.25 to $5.00. On average, they anticipate the company's stock price to reach $4.63 in the next twelve months. View analysts price targets for ACRX or view top-rated stocks among Wall Street analysts. How were AcelRx Pharmaceuticals' earnings last quarter? AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) released its quarterly earnings data on Monday, November, 15th. The specialty pharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.40). The specialty pharmaceutical company had revenue of $1.86 million for the quarter, compared to analyst estimates of $1.20 million. During the same period last year, the company earned ($2.00) earnings per share. When did AcelRx Pharmaceuticals' stock split? Shares of AcelRx Pharmaceuticals reverse split on the morning of Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of AcelRx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA). Who are AcelRx Pharmaceuticals' major shareholders? AcelRx Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Pamela P Palmer and Vincent J Angotti. View institutional ownership trends. This page (NASDAQ:ACRX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AcelRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.